Polar Capital Global Healthcare Trust announces Neal Ransome and Lisa Arnold to its Board as Independent Non-Executive Directors

– UK, London – Polar Capital Global Healthcare Trust plc (LSE:PCGH) announced the appointment of two new independent Non-executive Directors. Mr Neal Ransome will be appointed with effect from 13 December 2017 and Ms Lisa Arnold will be appointed with effect from 1 February 2018.

Mr Ransome is currently a non-executive director and chairman of the audit committee of Octopus AIM VCT Plc, a non-executive director of ProVen VCT Plc and a trustee and council member of the RSPB. Mr Ransome was formerly a corporate finance partner of PwC with extensive experience as a lead adviser on M&A activity in the pharmaceuticals and healthcare sectors.

Ms Arnold holds a number of trustee directorships, is the chairman of the investment committee of Allied Domecq Pension Fund and is non-executive director and chairman of the audit committee of PIMCO Europe Limited. Ms Arnold was formerly a global pharmaceuticals and healthcare analyst.

James Robinson, Chairman, commented “We are delighted that both Neal and Lisa have agreed to join the Board and we look forward to benefitting from their extensive experience and complementary skills.”

A resolution proposing the election of Mr Ransome and Ms Arnold as non-executive directors will be put to shareholders at the next Annual General Meeting of the Company due to be held in February 2018.

In addition to the above, both Mr Ransome and Ms Arnold will be appointed as Non-executive Directors of the Company’s subsidiary, PCGH ZDP plc, with the same effective appointment dates.

For more information : http://www.polarcapitalhealthcaretrust.com

- DisclaimerNews, data and statement included in this release are intended exclusively for information purposes. Product and brand names used in this release maybe trademarks or registered trade marks of their respective owners. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of this release. No data or statement in this release should be considered a recommendation for the purchase, retention or sale of the securities referred to herein.

Comments are closed.